Brixadi (buprenorphine-XR) for the Treatment of Opioid Use Disorder

This seven-hour webinar series from the Opioid Response Network (OPN) and American Osteopathic Academy of Addiction Medicine (AOAAM) will explore issues related to fentanyl use, including overdoses, xylazine, precipitated withdrawal, and the treatment of opioid use disorder using buprenorphine. Additionally, a new diagnostic and therapeutic approach regarding the treatment of methamphetamine use disorder will be discussed. This session is the fifth of seven webinars in the series.

Description:

During this lecture participants will learn how to treat patients with opioid use disorder using the newly FDA-approved injectable formulation of buprenorphine, Brixadi.

Learning Objectives:

At the conclusion of this seminar, participants will be able to:

1. Discuss how to start patients with OUD on Brixadi
2. Adjust the dose to alleviate opioid withdrawal, suppress cravings and use of opioids
3. Name typical adverse effects of the medication
4. Describe how the medication is to be administered and possible sites for injection